GONZALEZ DE REQUENA, Daniel

GONZALEZ DE REQUENA, Daniel  

Dip. DISCIPLINE MEDICO CHIRURGICHE (attivo dal 01/01/1900 al 30/04/2013)  

Mostra records
Risultati 1 - 17 di 17 (tempo di esecuzione: 0.045 secondi).
Titolo Data di pubblicazione Autore(i) File
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 2011 Gonzalez de Requena D; Bonora S; Viganò O; Calcagno A; Cometto C; D'Avolio A; Baietto L; Ghisetti V; Magnani S; Ferramosca S; Vitiello P; Galli M; Rusconi S; Di Perri G.
Cut-off values of ribavirin trough concentration for sustained virological response and for hematological toxicity in HCV/HIV-co-infected patients treated with RBV and Pegylated Interferon 2007 Aguilar Marucco D; Gonzalez de Requena D; Veronese L; Bonora S; Ibanez A; Baietto L; D'Avolio A; Sciandra M; Sinicco A; Di Perri G
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 2012 Calcagno A; Gonzalez de Requena D; Simiele M; D’Avolio A; Tettoni MC; Salassa B; Orofino G; Libanore V; Di Perri G; Bonora S
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 2009 Gonzalez de Requena D; Bonora S; Cometto C; Magnani S; D'Avolio A; Milia M; Vigano' O; Di Garbo A; Calcagno A; Siccardi M; Baietto L; Sciandra M; Rusconi S; Di Perri G.
Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens 2009 D. Gonzalez de Requena; S. Bonora; A. Calcagno; A. D’Avolio; O. Viganò; L. Baietto; C. Cometto; V. Ghisetti; M. Siccardi; S. Rusconi; G. Di Perri
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 2009 Calcagno A.; Bonora S.; Cometto C.; Fontana S.; Aguilar D.; D'Avolio A.; de Requena D. Gonzalez; Maiello A.; Sinicco A.; Di Perri G
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 2012 Dʼavolio A;Ciancio A;Siccardi M;Smedile A;Simiele M;Cusato J;Baietto L;Marucco DA;Cariti G;Calcagno A;Gonzalez de Requena D;Sciandra M;Troshina G;Caviglia GP;Bonora S;Rizzetto M;Di Perri G
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 2010 Calcagno A; Bonora S; Lucchini A; Maiello A; Dal Conte I; Gonzalez de Requena D; D’Avolio A; Siccardi M; Di Perri G
Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a novel NRTI-sparing regimen in naïve patiens 2011 Bonora S; Nozza S; Gonzalez de Requena D; Galli A; D'Avolio A; Calcagno A; Simiele M; Della Torre L; Lazzarin A; Di Perri G
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 2010 Calcagno A; Bonora S; Gonzalez De Requena D; Nozza S; D’Avolio A; Siccardi M; Simiele M; Castagna S; Lazzarin A; Di Perri G
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 2011 Bonora S; Gonzalez de Requena D; D'Avolio A; Calcagno A; Tettoni M; Siccardi M; Baietto L; Simiele M; Trentini L; Di Perri G
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 2008 Bonora S; D'Avolio A; Tettoni C; Siccardi M; Gonzalez de Requena D; Baietto L; Cometto C; Sciandra M; Trentini L; Di Perri G.
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 2010 Bonora S; D’Avolio A; Simiele M; Calcagno A; Baietto L; Chiesa M; Siccardi M; Gonzalez De Requena D; Sciandra M; Di Perri G.
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 2011 Calcagno A.; Bonora S.; Simiele M.; Audagnotto S.; Siccardi M.; de Requena D. Gonzalez; Romito A.; Imperiale D.; D'Avolio A.; Di Perri G
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 2013 Calcagno A;Gonzalez de Requena D;Simiele M;D'Avolio A;Tettoni M;Salassa B;Orofino G;Bramato C;Libanore V;Motta I;Bigliano P;Orsucci E;Di Perri G;Bonora S
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens. 2006 Bonora S; Gonzalez de Requena D; Calcagno A; Milia MG; D’Avolio A; Sciandra M; Garazzino S; Siccardi M; Sinicco A; Di Perri G.
Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20) 2006 Gonzalez de Requena D; Calcagno A; Bonora S; Ladetto L; D’Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G.